| 5.27 0.36 (7.33%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.94 | 1-year : | 7.91 |
| Resists | First : | 5.94 | Second : | 6.78 |
| Pivot price | 5.51  |
|||
| Supports | First : | 4.59 | Second : | 3.81 |
| MAs | MA(5) : | 5.11 |
MA(20) : | 5.5 |
| MA(100) : | 4.57 |
MA(250) : | 3.32 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 27.4 |
D(3) : | 27 |
| RSI | RSI(14): 48.9 |
|||
| 52-week | High : | 6.92 | Low : | 1.25 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IBRX ] has closed above bottom band by 35.6%. Bollinger Bands are 8.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.31 - 5.34 | 5.34 - 5.36 |
| Low: | 4.76 - 4.79 | 4.79 - 4.81 |
| Close: | 5.23 - 5.27 | 5.27 - 5.31 |
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
Fri, 19 Apr 2024
ImmunityBio (NASDAQ:IBRX) Stock Price Up 4.5% - MarketBeat
Thu, 18 Apr 2024
ImmunityBio (NASDAQ:IBRX) Shares Gap Down to $5.24 - MarketBeat
Wed, 17 Apr 2024
ImmunityBio (NASDAQ:IBRX) Shares Gap Up to $4.92 - MarketBeat
Thu, 28 Mar 2024
Will Immunitybio Inc (IBRX) Stay at the Top of the Healthcare Sector? - InvestorsObserver
Tue, 26 Mar 2024
Is Immunitybio Inc (IBRX) Stock a Smart Value? - InvestorsObserver
Tue, 19 Mar 2024
IBRX Stock Earnings: ImmunityBio Misses EPS, Beats Revenue for Q4 2023 - InvestorPlace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 677 (M) |
| Held by Insiders | 1.4527e+008 (%) |
| Held by Institutions | 79.6 (%) |
| Shares Short | 51,550 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.4285e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -60 % |
| Return on Assets (ttm) | 792.7 % |
| Return on Equity (ttm) | -52.2 % |
| Qtrly Rev. Growth | 622000 % |
| Gross Profit (p.s.) | 2260 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -367 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 5.2 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.24 |
| Dividend | 0 |
| Forward Dividend | 5.477e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|